about
Do advanced glycation end-products play a role in malaria susceptibility?The Role of AGE/RAGE Signaling in Diabetes-Mediated Vascular CalcificationOxidative Stress in Diabetic Nephropathy with Early Chronic Kidney DiseaseDietary Advanced Glycation End Products and Risk Factors for Chronic Disease: A Systematic Review of Randomised Controlled TrialsAdvanced Glycation End Products: Link between Diet and Ovulatory Dysfunction in PCOS?Development of nonalcoholic hepatopathy: contributions of oxidative stress and advanced glycation end productsRole of advanced glycation end products in cellular signalingOxidative stress and adipocyte biology: focus on the role of AGEsAdvanced glycation end products play adverse proinflammatory activities in osteoporosisAdvanced Glycation End Products, Diabetes, and Bone StrengthRelationship between Advanced Glycation End Products and Steroidogenesis in PCOSMass spectrometry-based methods for identifying oxidized proteins in disease: advances and challengesPlausible Roles for RAGE in Conditions Exacerbated by Direct and Indirect (Secondhand) Smoke Exposure.Dietary Sugars and Endogenous Formation of Advanced Glycation Endproducts: Emerging Mechanisms of Disease.Toxic AGE (TAGE) Theory for the Pathophysiology of the Onset/Progression of NAFLD and ALDGlyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical updateAdvanced glycation end products and oxidative stress in type 2 diabetes mellitus.Dietary advanced glycation end products and aging.Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications.Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics.The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes.Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes.Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeuticsRadical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond.MicroRNA in diabetic nephropathy: renin angiotensin, aGE/RAGE, and oxidative stress pathway.Nutrition and AGE-ing: Focusing on Alzheimer's Disease.Methylglyoxal-Derived Advanced Glycation Endproducts in Multiple Sclerosis.Advanced glycation end products, oxidative stress and diabetic nephropathy.Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndromeThe role of receptor for advanced glycation endproducts (RAGE) in infection.Histochemical approaches to assess cell-to-cell transmission of misfolded proteins in neurodegenerative diseases.The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach.Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.Mass spectrometric determination of early and advanced glycation in biology.Glycative Stress and Its Defense Machinery Glyoxalase 1 in Renal Pathogenesis.Clinical application prospect of umbilical cord-derived mesenchymal stem cells on clearance of advanced glycation end products through autophagy on diabetic wound.Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention.The Role of AOPP in Age-Related Bone Loss and the Potential Benefits of Berry Anthocyanins.Food Processing: The Influence of the Maillard Reaction on Immunogenicity and Allergenicity of Food Proteins.Advanced Glycation End Products in the Pathogenesis of Psoriasis.
P921
Q24471760-D471751D-261D-4FBF-8D52-7E535A3B736EQ26740003-B1C97DFC-5A54-4B47-81DF-0B0AB8B70C97Q26741451-EF457E0E-8E5B-42A3-9B12-B40A70BF8496Q26764769-81E98349-69F8-4E41-857E-DDB7472D504CQ26774333-0DEC2D32-1C0D-49EE-B8B9-18E33A1D1A9EQ26861308-42FA39A7-5B3C-4598-A8C9-618C9040AA43Q27003423-1D5C9E37-4CC5-43C1-9499-25ACAD91EBD1Q27015039-825F93E1-142E-49A5-A699-F14B06335218Q27024641-28E972CF-D0BE-43E0-8DEF-66AF43F40033Q28076977-505D9D0C-D19A-48DD-BB19-FDFC2BF94692Q28077960-DC2CF964-57A6-47DA-BB27-B842BFFDFB46Q28382957-5653A596-028C-4076-BB40-68780FBAE21BQ30235227-14399D23-2426-42BF-B674-D686DF03F200Q33616876-A604E3F6-CD3C-41F3-9535-B5C5C2938AAEQ33852213-3C684417-8B13-4C0D-9016-3FCBBF780C2FQ34286094-778513BF-1E9A-4849-9578-4CD9AF2A7596Q35255473-4D7B5C79-1D98-4FAC-A8BA-E2B1B8A769A5Q35670859-6BA6C162-51C9-4BBC-8D83-EF4CE9CA7BAEQ35766899-8EEFE52D-FE5F-428A-BD28-652DDE971DF1Q35809946-EAEFD8DD-A32C-4F76-A4BC-93910B1FF4BAQ36942530-FC18EE94-CD6E-4C7A-AD99-F4EB28A29A3EQ37156126-DDE8858B-72FE-4C9D-93A5-18D17D051DFCQ37156152-AEC3EBC2-A41C-45D6-B3CA-A20F1F09444FQ37291206-6F503ED8-044C-495D-8644-4E5EED906A72Q37419073-936E59EA-C610-484C-9AB2-51C06082A8D4Q37607470-52E08AA2-EF1B-4249-AC52-42CCB4B96C8FQ37690997-C0253E0B-36EA-459C-8C08-7AD77757AC61Q37780646-3FAD3470-E1C9-4ED0-8805-A112C9C5DCBAQ37831838-FA6C5894-7F32-4E97-A735-225E3797D5FFQ37860412-618DF10C-6761-4711-B097-7623A431FAEEQ38095350-333A4162-1CF2-4EA4-9A66-903680C3B416Q38241689-339FF94E-D3EB-41F6-885E-08C0A63D68DDQ38315999-13D31C2A-E57B-4581-A3D4-A084491A1FCCQ38839770-16C4F14B-2973-4D80-B847-9F2B982F1D44Q39096507-46B01053-6845-4C0F-B3D3-F1C6410F3D83Q39199171-9A35AD3D-9ED2-430F-A4AB-C109FB461F21Q39285661-A5502D4E-4188-4CD4-B1E2-8637A538503DQ39454196-9A808FD5-2CB7-4D67-B5C6-08B6D9FB5ACFQ41583979-15FD3589-0566-40C5-BABF-F2D1873E09CDQ46257931-81D3EA92-FB90-42E7-BAAC-D1C1FFEE64A9
P921
description
degraded protein components th ...... ertain pathological conditions
@en
name
protein degradation end products
@en
type
label
protein degradation end products
@en
altLabel
protein degradation end product
@en
prefLabel
protein degradation end products
@en
P486
P672
P486
P672
D12.776.643